NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Cancer Risk in Xeroderma Pigmentosum Heterozygotes

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

02-C-0313

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: No longer recruiting/follow-up only
Gender: Male & Female
Min Age: 1 mo
Max Age: 99 Years

Referral Letter Required

No

Population Exclusion(s)

Neonates

Keywords

Sun Exposure;
Xeroderma Pigmentosum;
Skin Cancer;
Family History;
HETEROZYGOTE;
Natural History

Recruitment Keyword(s)

Xeroderma Pigmentosum;
XP

Condition(s)

Xeroderma Pigmentosum;
Basal Cell Carcinoma;
Squamous Cell Carcinoma;
Melanoma;
Skin Cancer

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Cancer Institute

This study will determine if family members of patients with xeroderma pigmentosum (XP) have various abnormalities, including: skin abnormalities; nervous system abnormalities, such as hearing problems; skin, eye, or internal cancers, or other changes. XP is a rare inherited disease that involves an inability to repair damage to cell DNA (genetic material). It can affect several organ systems, including the skin, eye, nervous system, and bones. Patients have a more than thousand-fold increase in frequency in all major skin cancers.

Parents of patients with XP are carriers of the abnormal XP gene. Other family members may also be carriers of the abnormal XP gene. Carriers do not develop the disease themselves; symptoms develop only in children who have inherited the faulty gene from both parents. This study will try to clarify the genetic basis for XP and to understand the increased frequency of cancer in the disease.

XP patients who have been evaluated at the NIH Clinical Center and their relatives are eligible for this study. Newly diagnosed XP patients are also eligible. Spouses of relatives will also be included as control subjects.

Patients and their family members will undergo some or all of the following procedures:

- Parental permission to review the child s relevant medical records and pathology material from treatments or surgery for cancer or other related illnesses

- Medical history and physical examination, with particular attention to the skin and possible eye, hearing or neurological examinations

- Photographs to document skin and other physical findings

- Nuclear medicine scans to evaluate the brain and nervous system

- X-rays of the skull or other parts of the body

- Nervous system testing with an electroencephalogram (EEG), electroretinogram (ERG), electromyogram (EMG) or nerve conduction velocity measurement

- Collection of blood and skin samples for gene studies

- Establishment of cell lines from collected blood or tissues to study DNA repair, skin cancer, cancers related to XP, immune defects, and related studies.

- Biopsy (surgical removal of a small piece of tissue) of suspicious skin lesions for examination under a microscope

- Collection of a cheek cell sample, obtained by twirling a soft brush against the inside of the cheek

- Collection of a hair sample for microscopic examination and composition analysis

- Surgery to treat skin cancers or other lesions

--Back to Top--

Eligibility

INCLUSION CRITERIA:

Members of the XP families where the proband has previously been evaluated at the Clinical Center or is newly diagnosed under other approved protocols (primarily 99-C-0099) are eligible to participate in this study. Families with XP patients of any age (excluding neonates), gender or race are eligible for this study.

-On referral, patients with XP and families of XP patients will be considered for inclusion in the study if the proband has clinical documentation of features of XP and laboratory determination of the DNA repair defect. All relatives of XP patients including spouses are eligible to participate. A spouse of a blood relative of a patient with xeroderma pigmentosum would also be eligible.

-Ability of patient or Legally Authorized Representative (LAR) to sign a written informed consent document

EXCLUSION CRITERIA:

-Inability or unwillingness to provide family history information or tissue (skin, blood, buccal cells or hair) for laboratory studies.


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Kenneth H. Kraemer, M.D.
National Cancer Institute (NCI)
NIHBC 37 BG RM 4002
37 CONVENT DR
BETHESDA MD 20892
(240) 760-6139
kraemerk@mail.nih.gov

Deborah E. Tamura, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 37
Room 4002
37 Convent Drive
Bethesda, Maryland 20892
(240) 760-7355
dt220a@nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937

Clinical Trials Number:

NCT00046189

--Back to Top--